Form 4 for TRVI Trevi Therapeutics, Inc.
Accepted 2023-06-21 00:00:00 ET · period of report 2023-06-20 · accession 0001209191-23-038744 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-21 | 2023-06-20 | TRVI | Simon Farrell | Chief Commercial Off | M - OptEx | $0.51 | +6,250 | 45.6K | +16% | +$3,188 |
| D | 2023-06-21 | 2023-06-20 | TRVI | Simon Farrell | Chief Commercial Off | M - OptEx | $0.00 | -6,250 | 50.0K | -11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-20 | M | A | 6,250 | $0.51 | 45,650 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2023-06-20 | M | D | 6,250 | $0.00 | 50,000 | D | $0.51 · — to 2032-02-10 | 6,250 Common Stock | (F1) This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. |